• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Trinity Biotech plc

    3/13/25 7:30:13 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TRIB alert in real time by email
    6-K 1 zk2532861.htm 6-K


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549



    F O R M 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    For the month of March 2025

    TRINITY BIOTECH PLC
    (Name of Registrant)

    IDA Business Park
    Bray, Co. Wicklow, Ireland
     (Address of Principal Executive Office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐      

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes ☐    No ☒

    This Form 6-K is being incorporated by reference into our Registration Statements on Form F-3 (File Nos. 333-267160, 333-279017, 333-280391, 333-283273) and Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).


     EXPLANATORY NOTE

    On March 13, 2025, the Company issued a press release announcing the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. as its exclusive financial advisor to support its ongoing strategic realignment.

    A copy of the press release is filed herewith as Exhibit 99.1.


    EXHIBIT INDEX

    Exhibit
     
    Description
     
     
     
    99.1

    Trinity Biotech announces next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as its exclusive financial advisor.
     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    TRINITY BIOTECH PLC
     
       
    Trinity Biotech plc
     
       
    (Registrant)
     
           
     
    By:
    /s/ Louise Tallon
     
       
    Louise Tallon
     
       
    Chief Financial Officer
     

    Date: March 13, 2025


    Get the next $TRIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIB

    DatePrice TargetRatingAnalyst
    More analyst ratings